Market Overview

UPDATE: JP Morgan Upgrades MannKind to Neutral on Capitalization, Data Catalysts

Related MNKD
The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs
Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
MannKind - Afrezza Scripts Recover From Holiday Dip (Seeking Alpha)

JP Morgan raised its rating on MannKind (NASDAQ: MNKD) from Underweight to Neutral as the company appears to have sufficient capital to complete ongoing pipeline trials.

JP Morgan noted, "MNKD's quarterly report was essentially a nonevent. However, we are incrementally more confident that the company's recent (and highly dilutive) offering should enable funding of the Phase 3 AFFINITY trials through data in mid 2013. We feel relatively comfortable with Afrezza's clinical outlook based on decent (some would say mixed) past Ph3 data. Longer term, we believe a partner will be needed to launch the drug, and while a deal could meaningfully de-risk the stock, we are skeptical that one will be secured prior to the Ph3 data (and potentially not even after). Thus our commercial concerns remain."

MannKind closed at $1.93 on Thursday.

Latest Ratings for MNKD

Jun 2018Maxim GroupTerminatesSell
Mar 2018Maxim GroupDowngradesHoldSell
Nov 2017Maxim GroupDowngradesBuyHold

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (MNKD)

View Comments and Join the Discussion!